Furthermore, a recent study reported that the HDAC6 inhibitors ricolinostat and citarinostat could upregulate CD38 expression in MM cells and augment the efficacy of the anti-CD38 antibody daratumumab [28]. Here, HDAC6 is linked to Miyoshi myopathy.